Daniel Mansuri - Profile and Investment Details

Investor Profile

Daniel Mansuri is a Corporate Venture Capital based in Boston, Massachusetts, United States with a diverse investment portfolio that includes companies such as Proteostasis Therapeutics, Sanofi Ventures, Science 37, ImmuneXcite, Aetion, NeuroVia, Medisafe, Lysosomal Therapeutics, Sirtris Pharmaceuticals, UNUM Therapeutics, Immune Design, Common Sensing, GlycoMimetics, NGI, Yumanity Therapeutics, KAHR medical, Kymera Therapeutics, Ovid Therapeutics, Expansion Therapeutics, Imbria Pharmaceuticals, Cogent Biosciences, Bluebird Bio, Abcuro, NodThera, Fate Therapeutics, Minervax, Omada Health, Selecta Biosciences, Edimer PharmaceuticalsIcosavax, Navitor Pharmaceuticals, DiCE Molecules, Escient Pharmaceuticals, Evidation Health, Curisium, Click Therapeutics, Q32 Bio, Veralox Therapeutics, Lumena Pharmaceuticals, Lava Therapeutics, Inozyme, i2o Therapeutics, . Over time, Daniel Mansuri has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Daniel Mansuri is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Autoimmune Diseases, Wellness, Women Founded, Life Science, Engineering, Mobile, Biotechnology, Clinical Trials, Research, Digital Health, Medical, B2B, Therapeutics, Pharmaceuticals, Oncology may find it worthwhile to explore potential connections with Daniel Mansuri, as their portfolio suggests a familiarity and interest in this area.

Understanding Daniel Mansuri’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.